Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Corporate & Regulatory

Distribution agreement structure under Russian law in the pharmaceuticals sector: what in-house counsel need to know

Elena Pavlova · June 2026 · 10 min read

Russian pharma distribution law imposes constraints most foreign GCs do not anticipate. A structured guide for in-house counsel. Make an enquiry.

Unlike many civil law jurisdictions where a distribution agreement is treated as a straightforward commercial agency variant, Russian law places pharmaceutical distribution within a layered framework of civil, regulatory, and sector-specific obligations that interact in ways foreign in-house counsel frequently underestimate. A foreign manufacturer entering the Russian market through a local distributor must structure that agreement to satisfy not only the general requirements of Russian contract law but also the sector rules administered by the Federal Service for Healthcare Surveillance (Roszdravnadzor) and, where relevant, the parallel registration requirements of the Eurasian Economic Union. Getting the structure right at the outset reduces the risk of the agreement being unenforceable or the distributor operating outside its licensed scope — either of which can interrupt supply at a commercially critical moment.

What to prepare before drafting begins

Before instructing Russian counsel to draft or review a distribution agreement, in-house counsel should assemble the following:

Gathering these documents before drafting avoids a common pattern: a distribution agreement is signed, then revised when the regulatory review reveals that the distributor's licence does not cover one or more of the intended product categories.

If you are assessing whether a proposed Russian distributor meets the necessary regulatory threshold before contracting — make an enquiry: info@vetrovpartners.com |

What must a distribution agreement contain under Russian law?

Under the general framework of Russian civil legislation, a distribution agreement is most commonly structured as a supply agreement (dogovory postavki) combined with agency or commission elements, depending on whether the distributor acts in its own name or on behalf of the manufacturer. For pharmaceuticals, the distinction matters: a distributor acting in its own name takes title to the goods and bears responsibility for downstream quality compliance; one acting under a commission structure does not take title but must still hold the applicable licence for wholesale trade.

The agreement should specify, at a minimum: the product list by international non-proprietary name and registered trade name; the territory and any exclusivity conditions; pricing and discount mechanics including any maximum retail price obligations where Russian law imposes them; the duration and renewal mechanics; quality control obligations, including the procedure for handling product recalls and adverse event reporting under Russian pharmaceutical law; and the conditions for termination, including cure periods.

The product liability chain deserves particular attention. Under the prevailing approach of Russian courts, a distributor who has altered storage conditions or broken the cold chain may bear liability jointly with the manufacturer if the product causes harm. In-house counsel should ensure the agreement allocates this liability expressly and provides for indemnification, rather than relying on implied allocation under the general civil law rules.

Exclusivity clauses require coordination with FAS Russia guidelines on vertical agreements. As a general rule, exclusive distribution arrangements in the pharmaceutical sector are subject to antitrust review where the market share thresholds are exceeded, and provisions that prevent the distributor from selling competing products may be characterised as anti-competitive. Counsel should confirm the applicable market-share position before including a hard exclusivity clause.

For further background on the general legal framework applicable to distribution arrangements in Russia, see Distribution agreement structure: legal update and Distribution agreement structure: legal framework analysis.

Which regulatory authorisations does the distributor need?

Pharmaceutical distribution in Russia is a licensed activity. The distributor must hold a wholesale pharmaceutical licence, the scope of which specifies the categories of medicines it is authorised to handle — for example, narcotic and psychotropic substances require a separate supplementary licence and are subject to quota controls that must be reflected in the distribution agreement's product schedule.

State registration of the product is a prerequisite for distribution. If the manufacturer's product is registered under the EAEU unified registration procedure, that registration is recognised across all EAEU member states, including Russia, and the agreement should confirm which jurisdiction issued the marketing authorisation and the registered holder's identity — particularly important where the Russian legal entity of a foreign manufacturer group is not itself the registered holder.

Roszdravnadzor conducts periodic inspections of wholesale distributors, including review of storage conditions, documentation, and the distributor's internal quality management system. Foreign manufacturers who have entered into distribution agreements without verifying distributor compliance have, in practice, found themselves facing interruption when the distributor's licence was suspended or restricted following an inspection. For in-house counsel managing a Russian subsidiary or distributor network, the regulatory timeline for licence suspension proceedings leaves limited margin for contractual cure — a well-drafted agreement will include a representation as to current licence status and an obligation to notify the manufacturer immediately if any licence restriction is imposed or threatened.

Narcotics and controlled substances require the distributor to hold an additional authorisation and to comply with strict record-keeping and reporting obligations. Any agreement covering these categories should specify the distributor's obligations in terms that track the regulatory requirements directly, so that a breach of the regulatory obligation constitutes a breach of the distribution agreement and triggers the manufacturer's termination right.

For review of an existing or proposed Russian pharmaceutical distribution agreement against the current regulatory requirements — make an enquiry: info@vetrovpartners.com |

EAEU dimension and cross-border supply chain considerations

For manufacturers who distribute across more than one EAEU member state — Russia, Belarus, Kazakhstan, Kyrgyzstan, or Armenia — the distribution agreement structure requires an additional layer of analysis. The EAEU unified market for pharmaceuticals applies a common registration procedure and harmonised good distribution practice (GDP) standards, but the licensing of individual distributors remains a national matter in each member state.

Where a single distribution agreement is intended to govern supply across multiple EAEU jurisdictions, the agreement should specify the governing law (commonly Russian law, if the principal Russian counterpart is the contracting party), the dispute resolution forum, and the territorial scope of each licence held by the distributor. The risk of assuming that a Russian wholesale licence extends to distribution activities in Kazakhstan or Belarus is a recurring structural error: national licensing requirements differ, and a distributor licensed in Russia is not automatically authorised to operate in a neighbouring EAEU member state.

Currency and pricing provisions in cross-border EAEU supply arrangements also require attention. Russian pharmaceutical pricing regulation — including the state registration of prices for medicines included in the essential medicines list — applies to sales within Russia but does not extend automatically to cross-border EAEU supply. The agreement should distinguish between Russian-market sales and cross-border supply clearly, both to avoid applying Russian maximum price obligations to non-Russian transactions and to reflect the applicable VAT treatment in each jurisdiction.

For matters involving multi-jurisdictional distribution structures, the firm's Distribution & Franchising practice provides coordinated advice across the Russian and EAEU dimensions, working with trusted counsel in relevant member-state jurisdictions where local admission is required.

Termination, transition, and what happens when the agreement ends

Termination provisions in Russian pharmaceutical distribution agreements deserve more attention than they typically receive during drafting. Under Russian civil legislation, a fixed-term agreement terminates at its natural expiry without notice; an open-ended agreement requires advance notice of a specified period. In practice, many distribution agreements in the pharmaceutical sector are structured as open-ended arrangements renewed by conduct, which can create uncertainty about the applicable notice period.

The distributor's regulatory obligations do not terminate automatically when the commercial agreement ends. If the distributor holds product recall obligations, adverse event reporting duties, or pharmacovigilance obligations that arose during the agreement term, those obligations may survive termination under the applicable regulatory framework. The distribution agreement should address this explicitly: which party bears responsibility for post-termination regulatory obligations, who retains the product documentation, and who is responsible for any recall of product still in the supply chain at the date of termination.

Transition arrangements — moving a product from one distributor to another — require coordination between the incoming and outgoing distributors, notification to Roszdravnadzor in certain circumstances, and verification that the incoming distributor holds the requisite licence for each product category before the transition date. A transition timeline of fewer than 90 days is typically insufficient for a full product portfolio in the pharmaceutical sector; in-house counsel should build realistic transition periods into both the termination provisions and the new distributor agreement.

For a view of how Russian courts have approached distribution agreement disputes — including post-termination liability and stock clearance obligations — and how those outcomes affect the drafting of current agreements, the firm's Matters page contains representative matter descriptions.

For advice on structuring termination and transition provisions in a Russian pharmaceutical distribution agreement — make an enquiry: info@vetrovpartners.com |

Frequently asked questions

Q: Can a foreign manufacturer appoint an exclusive distributor for Russia without triggering FAS Russia antitrust scrutiny?

A: Exclusive distribution arrangements in Russia are not prohibited per se, but they are subject to scrutiny by the Federal Antimonopoly Service (FAS Russia) where the parties' combined market share exceeds the threshold above which vertical restraints are assessed. In the pharmaceutical sector, market definition is typically product-specific and regional, meaning that an arrangement that appears minor nationally may exceed the relevant threshold in a specific therapeutic category or federal district. Provisions that prevent the distributor from handling competing products — so-called "non-compete" clauses — attract additional attention. In-house counsel should ensure the market-share position is assessed before agreeing an exclusive clause, and that the agreement is structured so that the exclusivity obligation can be modified if the regulatory position changes.

Q: What documents does a Russian distributor need to produce to confirm its pharmaceutical licence is valid and current?

A: The distributor should produce a current extract from the State Register of Licences maintained by Roszdravnadzor, confirming the licence number, the activity types authorised, the premises and storage facilities covered, and the expiry date. Where the distributor handles narcotic or psychotropic substances, the additional authorisation certificate should be produced separately. A licence extract obtained more than 30 days before the agreement is signed should be reverified, as Roszdravnadzor may have imposed conditions or restrictions in the intervening period. The distribution agreement itself should include a representation that the licence is current and unrestricted, and an obligation to provide updated extracts at each contract year's commencement.

Q: How should a distribution agreement address product recalls for pharmaceuticals distributed in Russia?

A: Russian pharmaceutical legislation imposes mandatory recall obligations on the holder of the state registration certificate, which is typically the manufacturer or its Russian affiliate — not the distributor. However, the distributor is obliged to cooperate with recall procedures and to maintain records that allow product traceability through the supply chain. The distribution agreement should allocate recall costs, specify the distributor's obligations to identify and quarantine affected product within a defined timeframe, and confirm the communication protocol with Roszdravnadzor. Agreements that leave recall mechanics to be agreed at the time of an actual recall are operationally unreliable: a detailed recall annex, agreed in advance and tested through a table-top exercise, materially reduces the compliance risk.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry